Amenorrhea differential diagnosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Bot: Removing from Primary care)
 
(11 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Amenorrhea}}
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Amenorrhea]]
{{CMG}}; {{AE}} {{EG}}, {{MJ}}
{{CMG}}; {{AE}} {{EG}}, {{MJ}}


Line 8: Line 8:
== Differentiating Diseases with Amenorrhea from each other==
== Differentiating Diseases with Amenorrhea from each other==
As amenorrhea manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. Primary amenorrhea must be differentiated from other diseases that cause lack of [[menstrual cycle]], such as [[Mullerian agenesis]], [[Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency|3-beta-hydroxysteroid dehydrogenase type 2 deficiency]], [[androgen insensitivity syndrome]], [[Kallmann syndrome]], [[Turner syndrome]], and [[17-alpha-hydroxylase deficiency]]. In contrast, secondary amenorrhea must be differentiated from other diseases that cause [[menstrual cycle]] arrest, such as [[Primary ovarian failure|primary ovarian insufficiency]], [[hypothyroidism]], [[hyperprolactinemia]], [[polycystic ovary syndrome]], and [[Asherman's syndrome]].
As amenorrhea manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. Primary amenorrhea must be differentiated from other diseases that cause lack of [[menstrual cycle]], such as [[Mullerian agenesis]], [[Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency|3-beta-hydroxysteroid dehydrogenase type 2 deficiency]], [[androgen insensitivity syndrome]], [[Kallmann syndrome]], [[Turner syndrome]], and [[17-alpha-hydroxylase deficiency]]. In contrast, secondary amenorrhea must be differentiated from other diseases that cause [[menstrual cycle]] arrest, such as [[Primary ovarian failure|primary ovarian insufficiency]], [[hypothyroidism]], [[hyperprolactinemia]], [[polycystic ovary syndrome]], and [[Asherman's syndrome]].
 
<div style="width: 85%;">
<small>
{|
{|
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
Line 32: Line 33:
!Uterus
!Uterus
|-
|-
| rowspan="6" |'''Primary amenorrhea'''
| rowspan="6" style="background: #7d7d7d; color: #FFFFFF; padding: 5px; text-align: center;" |'''Primary amenorrhea'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Mullerian agenesis]]<ref name="pmid11023205">{{cite journal |vauthors=Folch M, Pigem I, Konje JC |title=Müllerian agenesis: etiology, diagnosis, and management |journal=Obstet Gynecol Surv |volume=55 |issue=10 |pages=644–9 |year=2000 |pmid=11023205 |doi= |url=}}</ref>'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Mullerian agenesis]]<ref name="pmid11023205">{{cite journal |vauthors=Folch M, Pigem I, Konje JC |title=Müllerian agenesis: etiology, diagnosis, and management |journal=Obstet Gynecol Surv |volume=55 |issue=10 |pages=644–9 |year=2000 |pmid=11023205 |doi= |url=}}</ref>'''
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |46 [[XX]]
| style="background: #F5F5F5; padding: 5px; text-align: center;" |46 [[XX]]
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px; text-align: center;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Urinary tract malformation|Urinary tract defects]]
* [[Urinary tract malformation|Urinary tract defects]]
Line 53: Line 54:
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency|3-beta-hydroxysteroid dehydrogenase type 2 deficiency]]
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency|3-beta-hydroxysteroid dehydrogenase type 2 deficiency]]
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |46 [[XX]]
| style="background: #F5F5F5; padding: 5px; text-align: center;" |46 [[XX]]
| style="background: #F5F5F5; padding: 5px;" |[[Clitoromegaly]]
| style="background: #F5F5F5; padding: 5px; text-align: center;" |[[Clitoromegaly]]
| style="background: #F5F5F5; padding: 5px;" | -/+
| style="background: #F5F5F5; padding: 5px; text-align: center;" | -/+
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Hyponatremia]]
* [[Hyponatremia]]
Line 72: Line 73:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Androgen insensitivity syndrome]]<ref name="pmid15237040">{{cite journal |vauthors= |title=Current evaluation of amenorrhea |journal=Fertil. Steril. |volume=82 |issue=1 |pages=266–72 |year=2004 |pmid=15237040 |doi=10.1016/j.fertnstert.2004.02.098 |url=}}</ref>'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Androgen insensitivity syndrome]]<ref name="pmid15237040">{{cite journal |vauthors= |title=Current evaluation of amenorrhea |journal=Fertil. Steril. |volume=82 |issue=1 |pages=266–72 |year=2004 |pmid=15237040 |doi=10.1016/j.fertnstert.2004.02.098 |url=}}</ref>'''
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |'''↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑'''
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |'''↑↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑↑'''
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |46 [[XY]]
| style="background: #F5F5F5; padding: 5px; text-align: center;" |46 [[XY]]
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px; text-align: center;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Undescended testes|Undescended testis]]
* [[Undescended testes|Undescended testis]]
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Kallmann syndrome]]<ref name="pmid7641400">{{cite journal |vauthors=Albanese A, Stanhope R |title=Investigation of delayed puberty |journal=Clin. Endocrinol. (Oxf) |volume=43 |issue=1 |pages=105–10 |year=1995 |pmid=7641400 |doi= |url=}}</ref>'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Kallmann syndrome]]<ref name="pmid7641400">{{cite journal |vauthors=Albanese A, Stanhope R |title=Investigation of delayed puberty |journal=Clin. Endocrinol. (Oxf) |volume=43 |issue=1 |pages=105–10 |year=1995 |pmid=7641400 |doi= |url=}}</ref>'''
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |↓↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓↓
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |46 [[XX]]
| style="background: #F5F5F5; padding: 5px; text-align: center;" |46 [[XX]]
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px; text-align: center;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px; text-align: center;" | -
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Anosmia]]/[[Hyposmia]]
* [[Anosmia]]/[[Hyposmia]]
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Turner syndrome]]<ref name="pmid15371580">{{cite journal |vauthors=Sybert VP, McCauley E |title=Turner's syndrome |journal=N. Engl. J. Med. |volume=351 |issue=12 |pages=1227–38 |year=2004 |pmid=15371580 |doi=10.1056/NEJMra030360 |url=}}</ref>'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Turner syndrome]]<ref name="pmid15371580">{{cite journal |vauthors=Sybert VP, McCauley E |title=Turner's syndrome |journal=N. Engl. J. Med. |volume=351 |issue=12 |pages=1227–38 |year=2004 |pmid=15371580 |doi=10.1056/NEJMra030360 |url=}}</ref>'''
| style="background: #F5F5F5; padding: 5px;" |↓↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓↓
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |'''↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑'''
| style="background: #F5F5F5; padding: 5px;" |'''↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑'''
| style="background: #F5F5F5; padding: 5px;" |'''↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑'''
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |[[Turner syndrome|45 XO]]
| style="background: #F5F5F5; padding: 5px; text-align: center;" |[[Turner syndrome|45 XO]]
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" | +/-
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/-
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Webbed neck]]
* [[Webbed neck]]
Line 127: Line 128:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[17-alpha-hydroxylase deficiency]]'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[17-alpha-hydroxylase deficiency]]'''
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |'''↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑'''
| style="background: #F5F5F5; padding: 5px;" |'''↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑'''
| style="background: #F5F5F5; padding: 5px;" |'''↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑'''
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |46 [[XY]]
| style="background: #F5F5F5; padding: 5px; text-align: center;" |46 [[XY]]
| style="background: #F5F5F5; padding: 5px;" |[[Infantilism]]
| style="background: #F5F5F5; padding: 5px; text-align: center;" |[[Infantilism]]
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px; text-align: center;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px; text-align: center;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px; text-align: center;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Hypertension]]
* [[Hypertension]]
|-
|-
| rowspan="5" |'''Secondary amenorrhea'''
| rowspan="5" style="background: #7d7d7d; color: #FFFFFF; padding: 5px; text-align: center;" |'''Secondary amenorrhea'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Primary ovarian failure|Primary ovarian insufficiency]]<ref name="pmid19196677">{{cite journal |vauthors=Nelson LM |title=Clinical practice. Primary ovarian insufficiency |journal=N. Engl. J. Med. |volume=360 |issue=6 |pages=606–14 |year=2009 |pmid=19196677 |pmc=2762081 |doi=10.1056/NEJMcp0808697 |url=}}</ref>'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Primary ovarian failure|Primary ovarian insufficiency]]<ref name="pmid19196677">{{cite journal |vauthors=Nelson LM |title=Clinical practice. Primary ovarian insufficiency |journal=N. Engl. J. Med. |volume=360 |issue=6 |pages=606–14 |year=2009 |pmid=19196677 |pmc=2762081 |doi=10.1056/NEJMcp0808697 |url=}}</ref>'''
| style="background: #F5F5F5; padding: 5px;" |↓↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓↓
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |'''↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑'''
| style="background: #F5F5F5; padding: 5px;" |'''↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑'''
| style="background: #F5F5F5; padding: 5px;" |'''↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑'''
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |46 [[XX]]
| style="background: #F5F5F5; padding: 5px; text-align: center;" |46 [[XX]]
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Osteoporosis]]
* [[Osteoporosis]]
Line 165: Line 166:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Hypothyroidism]]<ref name="pmid14575026">{{cite journal |vauthors=Kalro BN |title=Impaired fertility caused by endocrine dysfunction in women |journal=Endocrinol. Metab. Clin. North Am. |volume=32 |issue=3 |pages=573–92 |year=2003 |pmid=14575026 |doi= |url=}}</ref>'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Hypothyroidism]]<ref name="pmid14575026">{{cite journal |vauthors=Kalro BN |title=Impaired fertility caused by endocrine dysfunction in women |journal=Endocrinol. Metab. Clin. North Am. |volume=32 |issue=3 |pages=573–92 |year=2003 |pmid=14575026 |doi= |url=}}</ref>'''
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |'''↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑'''
| style="background: #F5F5F5; padding: 5px;" |'''↑↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑↑'''
| style="background: #F5F5F5; padding: 5px;" |↓↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓↓
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |46 [[XX]]
| style="background: #F5F5F5; padding: 5px; text-align: center;" |46 [[XX]]
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Fatigue]]
* [[Fatigue]]
Line 184: Line 185:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Hyperprolactinemia]]<ref name="pmid15024895">{{cite journal |vauthors=Pickett CA |title=Diagnosis and management of pituitary tumors: recent advances |journal=Prim. Care |volume=30 |issue=4 |pages=765–89 |year=2003 |pmid=15024895 |doi= |url=}}</ref>'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Hyperprolactinemia]]<ref name="pmid15024895">{{cite journal |vauthors=Pickett CA |title=Diagnosis and management of pituitary tumors: recent advances |journal=Prim. Care |volume=30 |issue=4 |pages=765–89 |year=2003 |pmid=15024895 |doi= |url=}}</ref>'''
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |'''↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑'''
| style="background: #F5F5F5; padding: 5px;" |46 [[XX]]
| style="background: #F5F5F5; padding: 5px; text-align: center;" |46 [[XX]]
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Galactorrhea]]
* [[Galactorrhea]]
Line 204: Line 205:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Polycystic ovary syndrome]]<ref name="pmid12434783">{{cite journal |vauthors= |title=ACOG practice bulletin clinical management guidelines for obstetrician-gynecologists. Number 40, November 2002 |journal=Obstet Gynecol |volume=100 |issue=5 Pt 1 |pages=1045–50 |year=2002 |pmid=12434783 |doi= |url=}}</ref>'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Polycystic ovary syndrome]]<ref name="pmid12434783">{{cite journal |vauthors= |title=ACOG practice bulletin clinical management guidelines for obstetrician-gynecologists. Number 40, November 2002 |journal=Obstet Gynecol |volume=100 |issue=5 Pt 1 |pages=1045–50 |year=2002 |pmid=12434783 |doi= |url=}}</ref>'''
| style="background: #F5F5F5; padding: 5px;" |↓↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓↓
| style="background: #F5F5F5; padding: 5px;" |↓↓
| style="background: #F5F5F5; padding: 5px; text-align: center;" |↓↓
| style="background: #F5F5F5; padding: 5px;" |'''↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑'''
| style="background: #F5F5F5; padding: 5px;" |'''↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑'''
| style="background: #F5F5F5; padding: 5px;" |'''↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑'''
| style="background: #F5F5F5; padding: 5px;" |'''↑'''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |'''↑'''
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |46 [[XX]]
| style="background: #F5F5F5; padding: 5px; text-align: center;" |46 [[XX]]
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Hirsutism]]
* [[Hirsutism]]
Line 223: Line 224:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Asherman's syndrome]]<ref>{{cite book | last = Fritz | first = Marc | title = Clinical gynecologic endocrinology and infertility | publisher = Wolters Kluwer Health/Lippincott Williams & Wilkins | location = Philadelphia | year = 2011 | isbn = 978-0781779685 }}</ref>'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''[[Asherman's syndrome]]<ref>{{cite book | last = Fritz | first = Marc | title = Clinical gynecologic endocrinology and infertility | publisher = Wolters Kluwer Health/Lippincott Williams & Wilkins | location = Philadelphia | year = 2011 | isbn = 978-0781779685 }}</ref>'''
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" |46 [[XX]]
| style="background: #F5F5F5; padding: 5px; text-align: center;" |46 [[XX]]
| style="background: #F5F5F5; padding: 5px;" |Nl
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Nl
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* History of [[uterus]] [[surgery]]
* History of [[uterus]] [[surgery]]
* [[Uterus]] scarring
* [[Uterus]] scarring
|}
|}
 
</small>
Amenorrhea must be differentiated from other causes of irregular menses.
</div>
 
{| class="wikitable"
!Disease
!Differentiating Features
|-
|[[Pregnancy]]
|
* Pregnancy always should be excluded in a patient with a history of amenorrhea
 
* Features include amenorrhea or oligomenorrhea, abnormal uterine bleeding, nausea/vomiting, cravings, weight gain (although not in the early stages and not if vomiting), polyuria, abdominal cramps and constipation, fatigue, dizziness/lightheadedness, and increased pigmentation (moles, nipples)
 
* Uterine enlargement is detectable on abdominal examination at approximately 14 weeks of gestation
 
* Ectopic pregnancy may cause oligomenorrhea, amenorrhea, or abnormal uterine bleeding with abdominal pain and sometimes subtle or absent physical symptoms and signs of pregnancy
|-
|Hypothalamic amenorrhea
|
* Diagnosis of exclusion
* Seen in athletes, people on crash diets, patients with significant systemic illness, and those experiencing undue stress or anxiety
* Predisposing features are as follows weight loss, particularly if features of anorexia nervosa are present or the BMI is <19 kg/m2
* Recent administration of depot medroxyprogesterone, which may suppress ovarian activity for 6 months to a year
* Use of dopamine agonists (eg, antidepressants) and major tranquilizers
* Hyperthyroidism
* In patients with weight loss related to anorexia nervosa, fine hair growth (lanugo) may occur all over the body, but it differs from hirsutism in its fineness and wide distribution
|-
|[[Primary amenorrhea]]
|
* Causes include reproductive system abnormalities, chromosomal abnormalities, or delayed puberty
* If secondary sexual characteristics are present, an anatomic abnormality (eg, imperforate hymen, which is rare) should be considered
* If secondary sexual characteristics are absent, a chromosomal abnormality (eg, Turner syndrome ) or delayed puberty should be considered
|-
|[[Cushing's syndrome|Cushing syndrome]]
|
* Cushing syndrome is due to excessive glucocorticoid secretion from the adrenal glands, either primarily or secondary to stimulation from pituitary or ectopic hormones; can also be caused by exogenous steroid use
 
* Features include hypertension, weight gain (central distribution), acne, and abdominal striae Patients have low plasma sodium levels and elevated plasma cortisol levels on dexamethasone suppression testing
|-
|[[Hyperprolactinemia]]
|
* Mild hyperprolactinemia may occur as part of PCOS-related hormonal dysfunction
 
* Other causes include stress, lactation, and use of dopamine antagonists
* A prolactinoma of the pituitary gland is an uncommon cause and should be suspected if prolactin levels are very high (>200 ng/mL)
* Physical examination findings are usually normal
* As in patients with PCOS, hyperprolactinemia may be associated with mild galactorrhea and oligomenorrhea or amenorrhea; however, galactorrhea also can occur with nipple stimulation and/or stress when prolactin levels are within normal ranges
* A large prolactinoma may cause headaches and visual field disturbance due to pressure on the optic chiasm, classically a gradually increasing bi-temporal hemianopsia
|-
|Ovarian or adrenal tumor
|
* Benign ovarian tumors and ovarian cancer are rare causes of excessive androgen secretion; adrenocortical tumors also can increase the production of sex hormones
* Abdominal swelling or mass, abdominal pain due to fluid leakage or torsion, dyspareunia, abdominal ascites, and features of metastatic disease may be present
* Features of androgenization include hirsutism, weight gain, oligomenorrhea or amenorrhea, acne, clitoral hypertrophy, deepening of the voice, and high serum androgen (eg, testosterone, other androgens) levels
* In patients with an androgen-secreting tumor, serum testosterone is not suppressed by dexamethasone
|-
|[[Congenital adrenal hyperplasia]]
|
* Congenital adrenal hyperplasia is a rare genetic condition resulting from 21-hydroxylase deficiency
* The late-onset form presents at or around menarche Patients have features of androgenization and subfertility
* Affects approximately 1% of hirsute patients More common in Ashkenazi Jews (19%), inhabitants of the former Yugoslavia (12%), and Italians (6%)
* Associated with high levels of 17-hydroxyprogesterone
* A short adrenocorticotropic hormone stimulation test with measurement of serum17-hydroxyprogesterone confirms the diagnosis Assays of a variety of androgenic hormones help define other rare adrenal enzyme deficiencies, which present similarly to 21-hydroxylase deficiency
|-
|Anabolic steroid abuse
|
* Anabolic steroids are synthetic hormones that imitate the actions of testosterone by increasing muscle bulk and strength
* Should be considered if the patient is a serious sportswoman or bodybuilder
* Features include virilization (including acne and hirsutism), often increased muscle bulk in male pattern, oligomenorrhea or amenorrhea, clitoromegaly, gastritis, hepatic enlargement, alopecia, and aggression
* Altered liver function test results are seen
|-
|[[Hirsutism]]
|
* Hirsutism is excessive facial and body hair, usually coarse and in a male pattern of distribution
* Approximately 10% of women report unwanted facial hair
* There is often a family history and typically some Mediterranean or Middle Eastern ancestry
* May also result from use of certain medications, both androgens, and others including danazol, glucocorticoids, cyclosporine, and phenytoin
* Menstrual history is normal
* When the cause is genetic, the excessive hair, especially on the face (upper lip), is present throughout adulthood, and there is no virilization
* When secondary to medications, the excessive hair is of new onset, and other features of virilization, such as acne and deepened voice, may be present
|}
 
 
Amenorrhea must be differentiated from other causes of irregular menses.
{| class="wikitable"
!Disease
!Differentiating Features
|-
|[[Pregnancy]]
|
* Pregnancy always should be excluded in a patient with a history of amenorrhea
 
* Features include amenorrhea or oligomenorrhea, abnormal uterine bleeding, nausea/vomiting, cravings, weight gain (although not in the early stages and not if vomiting), polyuria, abdominal cramps and constipation, fatigue, dizziness/lightheadedness, and increased pigmentation (moles, nipples)
 
* Uterine enlargement is detectable on abdominal examination at approximately 14 weeks of gestation
 
* Ectopic pregnancy may cause oligomenorrhea, amenorrhea, or abnormal uterine bleeding with abdominal pain and sometimes subtle or absent physical symptoms and signs of pregnancy
|-
|Hypothalamic amenorrhea
|
* Diagnosis of exclusion
* Seen in athletes, people on crash diets, patients with significant systemic illness, and those experiencing undue stress or anxiety
* Predisposing features are as follows weight loss, particularly if features of anorexia nervosa are present or the BMI is <19 kg/m2
* Recent administration of depot medroxyprogesterone, which may suppress ovarian activity for 6 months to a year
* Use of dopamine agonists (eg, antidepressants) and major tranquilizers
* Hyperthyroidism
* In patients with weight loss related to anorexia nervosa, fine hair growth (lanugo) may occur all over the body, but it differs from hirsutism in its fineness and wide distribution
|-
|[[Primary amenorrhea]]
|
* Causes include reproductive system abnormalities, chromosomal abnormalities, or delayed puberty
* If secondary sexual characteristics are present, an anatomic abnormality (eg, imperforate hymen, which is rare) should be considered
* If secondary sexual characteristics are absent, a chromosomal abnormality (eg, Turner syndrome ) or delayed puberty should be considered
|-
|[[Cushing's syndrome|Cushing syndrome]]
|
* Cushing syndrome is due to excessive glucocorticoid secretion from the adrenal glands, either primarily or secondary to stimulation from pituitary or ectopic hormones; can also be caused by exogenous steroid use
 
* Features include hypertension, weight gain (central distribution), acne, and abdominal striae Patients have low plasma sodium levels and elevated plasma cortisol levels on dexamethasone suppression testing
|-
|[[Hyperprolactinemia]]
|
* Mild hyperprolactinemia may occur as part of PCOS-related hormonal dysfunction
 
* Other causes include stress, lactation, and use of dopamine antagonists
* A prolactinoma of the pituitary gland is an uncommon cause and should be suspected if prolactin levels are very high (>200 ng/mL)
* Physical examination findings are usually normal
* As in patients with PCOS, hyperprolactinemia may be associated with mild galactorrhea and oligomenorrhea or amenorrhea; however, galactorrhea also can occur with nipple stimulation and/or stress when prolactin levels are within normal ranges
* A large prolactinoma may cause headaches and visual field disturbance due to pressure on the optic chiasm, classically a gradually increasing bi-temporal hemianopsia
|-
|Ovarian or adrenal tumor
|
* Benign ovarian tumors and ovarian cancer are rare causes of excessive androgen secretion; adrenocortical tumors also can increase the production of sex hormones
* Abdominal swelling or mass, abdominal pain due to fluid leakage or torsion, dyspareunia, abdominal ascites, and features of metastatic disease may be present
* Features of androgenization include hirsutism, weight gain, oligomenorrhea or amenorrhea, acne, clitoral hypertrophy, deepening of the voice, and high serum androgen (eg, testosterone, other androgens) levels
* In patients with an androgen-secreting tumor, serum testosterone is not suppressed by dexamethasone
|-
|[[Congenital adrenal hyperplasia]]
|
* Congenital adrenal hyperplasia is a rare genetic condition resulting from 21-hydroxylase deficiency
* The late-onset form presents at or around menarche Patients have features of androgenization and subfertility
* Affects approximately 1% of hirsute patients More common in Ashkenazi Jews (19%), inhabitants of the former Yugoslavia (12%), and Italians (6%)
* Associated with high levels of 17-hydroxyprogesterone
* A short adrenocorticotropic hormone stimulation test with measurement of serum17-hydroxyprogesterone confirms the diagnosis Assays of a variety of androgenic hormones help define other rare adrenal enzyme deficiencies, which present similarly to 21-hydroxylase deficiency
|-
|Anabolic steroid abuse
|
* Anabolic steroids are synthetic hormones that imitate the actions of testosterone by increasing muscle bulk and strength
* Should be considered if the patient is a serious sportswoman or bodybuilder
* Features include virilization (including acne and hirsutism), often increased muscle bulk in male pattern, oligomenorrhea or amenorrhea, clitoromegaly, gastritis, hepatic enlargement, alopecia, and aggression
* Altered liver function test results are seen
|-
|[[Hirsutism]]
|
* Hirsutism is excessive facial and body hair, usually coarse and in a male pattern of distribution
* Approximately 10% of women report unwanted facial hair
* There is often a family history and typically some Mediterranean or Middle Eastern ancestry
* May also result from use of certain medications, both androgens, and others including danazol, glucocorticoids, cyclosporine, and phenytoin
* Menstrual history is normal
* When the cause is genetic, the excessive hair, especially on the face (upper lip), is present throughout adulthood, and there is no virilization
* When secondary to medications, the excessive hair is of new onset, and other features of virilization, such as acne and deepened voice, may be present
|}


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WH}}
{{WS}}


[[Category:Needs content]]
[[Category:Medicine]]
 
[[Category:Overview complete]]
[[Category:Disease]]
[[Category:Endocrinology]]
[[Category:Endocrinology]]
[[Category:Up-To-Date]]
[[Category:Gynecology]]
[[Category:Gynecology]]
 
[[Category:Obstetrics]]
 
{{WH}}
{{WS}}

Latest revision as of 20:22, 29 July 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2], Mehrian Jafarizade, M.D [3]

Overview

As amenorrhea manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. Primary amenorrhea must be differentiated from other diseases that cause lack of menstrual cycle, such as Mullerian agenesis, 3-beta-hydroxysteroid dehydrogenase type 2 deficiency, androgen insensitivity syndrome, Kallmann syndrome, Turner syndrome, and 17-alpha-hydroxylase deficiency. In contrast, secondary amenorrhea must be differentiated from other diseases that cause menstrual cycle arrest, such as primary ovarian insufficiency, hypothyroidism, hyperprolactinemia, polycystic ovary syndrome, and Asherman's syndrome.

Differentiating Diseases with Amenorrhea from each other

As amenorrhea manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. Primary amenorrhea must be differentiated from other diseases that cause lack of menstrual cycle, such as Mullerian agenesis, 3-beta-hydroxysteroid dehydrogenase type 2 deficiency, androgen insensitivity syndrome, Kallmann syndrome, Turner syndrome, and 17-alpha-hydroxylase deficiency. In contrast, secondary amenorrhea must be differentiated from other diseases that cause menstrual cycle arrest, such as primary ovarian insufficiency, hypothyroidism, hyperprolactinemia, polycystic ovary syndrome, and Asherman's syndrome.

Group Diseases Laboratory Findings Physical Examination Other Findings
Estrogen Progesterone GnRH LH FSH Androgen TSH T4 PRL Karyotype Externl genitalia Breast development Pubic hair Uterus
Primary amenorrhea Mullerian agenesis[1] Nl Nl Nl Nl Nl Nl Nl Nl Nl 46 XX Nl + + -
3-beta-hydroxysteroid dehydrogenase type 2 deficiency Nl Nl Nl Nl Nl ↓ Nl Nl Nl 46 XX Clitoromegaly -/+ + +
Androgen insensitivity syndrome[2] Nl Nl ↓ ↑ Nl ↑↑ Nl Nl Nl 46 XY Nl + + -
Kallmann syndrome[3] ↓ ↓ ↓↓ ↓ ↓ ↓ Nl Nl Nl 46 XX Nl - - +
Turner syndrome[4] ↓↓ ↓ ↑ ↑ ↑ Nl Nl Nl Nl 45 XO Nl +/- + +
17-alpha-hydroxylase deficiency ↓ Nl ↑ ↑ ↑ ↓ Nl Nl Nl 46 XY Infantilism - - -
Secondary amenorrhea Primary ovarian insufficiency[5] ↓↓ ↓ ↑ ↑ ↑ Nl Nl Nl Nl 46 XX Nl + + +
Hypothyroidism[6] Nl Nl Nl Nl Nl ↑ ↑↑ ↓↓ Nl 46 XX Nl + + +
Hyperprolactinemia[7] ↓ ↓ ↓ ↓ ↓ ↓ Nl Nl ↑ 46 XX Nl + + +
Polycystic ovary syndrome[8] ↓↓ ↓↓ ↑ ↑ ↑ ↑ Nl Nl Nl 46 XX Nl + + +
Asherman's syndrome[9] Nl Nl Nl Nl Nl Nl Nl Nl Nl 46 XX Nl + + +

References

  1. ↑ Folch M, Pigem I, Konje JC (2000). "Müllerian agenesis: etiology, diagnosis, and management". Obstet Gynecol Surv. 55 (10): 644–9. PMID 11023205.
  2. ↑ "Current evaluation of amenorrhea". Fertil. Steril. 82 (1): 266–72. 2004. doi:10.1016/j.fertnstert.2004.02.098. PMID 15237040.
  3. ↑ Albanese A, Stanhope R (1995). "Investigation of delayed puberty". Clin. Endocrinol. (Oxf). 43 (1): 105–10. PMID 7641400.
  4. ↑ Sybert VP, McCauley E (2004). "Turner's syndrome". N. Engl. J. Med. 351 (12): 1227–38. doi:10.1056/NEJMra030360. PMID 15371580.
  5. ↑ Nelson LM (2009). "Clinical practice. Primary ovarian insufficiency". N. Engl. J. Med. 360 (6): 606–14. doi:10.1056/NEJMcp0808697. PMC 2762081. PMID 19196677.
  6. ↑ Kalro BN (2003). "Impaired fertility caused by endocrine dysfunction in women". Endocrinol. Metab. Clin. North Am. 32 (3): 573–92. PMID 14575026.
  7. ↑ Pickett CA (2003). "Diagnosis and management of pituitary tumors: recent advances". Prim. Care. 30 (4): 765–89. PMID 15024895.
  8. ↑ "ACOG practice bulletin clinical management guidelines for obstetrician-gynecologists. Number 40, November 2002". Obstet Gynecol. 100 (5 Pt 1): 1045–50. 2002. PMID 12434783.
  9. ↑ Fritz, Marc (2011). Clinical gynecologic endocrinology and infertility. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. ISBN 978-0781779685.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Amenorrhea_differential_diagnosis&oldid=1634581"